300. IgG4-related disease
[
20 clinical trials,
19 drugs（DrugBank:
13 drugs),
8 target genes / 72 target pathways ]
Searched query = "IgG4 related disease", "Autoimmune pancreatitis", "IgG4 related sclerosing cholangitis", "IgG4 related lacrimal gland, orbital, and salivary gland lesions", "IgG4 related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04125511 | November 1, 2019 | 4 November 2019 | Characterizing IgG4-RD With 68Ga-FAPI PET/CT | Characterizing IgG4-related Disease With 68Ga-FAPI PET/CT | IgG4-related Disease | Drug: 68Ga-FAPI | Peking Union Medical College Hospital | Not recruiting | 18 Years | 90 Years | All | 100 | Early Phase 1 | ||
| 2 | NCT04124861 | October 15, 2019 | 22 October 2019 | Withdraw Drug in Stable IgG4-Related Disease | Evaluation and Prediction of Relapse Risk After Glucocorticoid and Immunosuppressant Withdrawal in Patients With Stable IgG4 Related Disease: An Open-labeled Multi-centric Randomized Controlled Study From China | Autoimmune Diseases | Drug: Drug free, IS monotherapy and GC combined with IS | Peking Union Medical College Hospital | Chinese PLA General Hospital;Peking University People's Hospital;The People's Hospital of Hebei Province;Shengjing Hospital;Tongji Hospital | Not recruiting | 18 Years | 70 Years | All | 138 | N/A | |
| 3 | NCT03669861 | November 13, 2018 | 26 November 2018 | Safety and Efficacy of Abatacept in IgG4-Related Disease | A Prospective, Open-label, Single Center Abatacept in IgG4-Related Disease 10-patient Proof-of-concept Study | IgG4-related Disease | Drug: Abatacept | Massachusetts General Hospital | Bristol-Myers Squibb | Recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States |
| 4 | JPRN-UMIN000030735 | 2018/01/15 | 22 July 2019 | Diagnostic accuracy of contrast enhanced endoscopic ultrasonography in pancreatbiliary disease | Diagnostic accuracy of contrast enhanced endoscopic ultrasonography in pancreatbiliary disease - A clinical trial of contrast enhanced endoscopic ultrasonography in the pancreatobiliary disease | Pancreas tumor, Chronic pancreatitis, Autoimmune pancreatitis, Gallblader polyp, Biliary tract tumor | Contrast enhanced endoscopic ultrasonography using perflubutane MRI enhanced CT endoscopic ultrasonography without perflubutane | Department of Endoscopy The Jikei University School of Medicine | Not Recruiting | 20years-old | 100years-old | Male and Female | 786 | Not selected | Japan | |
| 5 | NCT03368274 | September 1, 2017 | 11 June 2018 | To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom | To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom | IgG4-related Disease | Drug: T 614 | Wen Zhang | Recruiting | 18 Years | 70 Years | All | 30 | Phase 4 | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2017-002214-31-BE | 26 November 2018 | Study to Evaluate The Safety And Effectiveness of XmAb®5871 In Patients With IgG4-Related Disease (INDIGO) | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb®5871 in Patients with IgG4-Related Disease (INDIGO) | IgG4-Related Disease MedDRA version: 20.0 Level: LLT Classification code 10071581 Term: IgG4 related sclerosing disease System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: XmAb5871 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: XmAb5871 Current Sponsor code: XmAb5871 Other descriptive name: XMAB5871 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 125.0- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Xencor, Inc. | Not Available | Female: yes Male: yes | 240 | Phase 3 | United States;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Belgium;Germany;Netherlands;Sweden | ||||
| 7 | EUCTR2017-002214-31-NL | 20 August 2018 | Study to Evaluate The Safety And Effectiveness of XmAb®5871 In Patients With IgG4-Related Disease (INDIGO) | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb®5871 in Patients with IgG4-Related Disease (INDIGO) | IgG4-Related Disease MedDRA version: 20.0 Level: LLT Classification code 10071581 Term: IgG4 related sclerosing disease System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: XmAb5871 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: XmAb5871 Current Sponsor code: XmAb5871 Other descriptive name: XMAB5871 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 125.0- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Xencor, Inc. | Not Available | Female: yes Male: yes | 240 | Phase 3 | United States;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Belgium;Netherlands;Germany;Sweden | ||||
| 8 | JPRN-UMIN000022633 | 2016/06/06 | 2 April 2019 | Efficacy and safety of low-dose steroid treatment in asymptomatic patients with autoimmune pancreatitis. | autoimmune pancreatitis | Steroid treatment (total 56 weeks) Induction ~ 4 weeks : Prednisolone 10mg/day 4 weeks ~ 48 weeks : Prednisolone 5mg/day 48 weeks ~ 52 weeks : Prednisolone 2.5mg/day 52 weeks ~ 56 weeks : Prednisolone 1mg/day | Osaka University | Not Recruiting | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan | ||
| 9 | NCT02797665 | May 2016 | 20 August 2018 | Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and/or Immunoglobulin G4-related Sclerosing Cholangitis by Corticosteroids | Autoimmune Pancreatitis;IgG4-related Sclerosing Cholangitis;Obstructive Jaundice | Drug: corticosteroids;Procedure: biliary stent | Peking Union Medical College Hospital | Not recruiting | 18 Years | N/A | All | 30 | N/A | China | ||
| 10 | NCT02705638 | April 2016 | 15 July 2019 | Treatment of IgG4-Related Disease With Revlimid and Rituximab | Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial | Immunoglobulin G Subclass 4 Related Disease;IgG4-related Disease;Autoimmune Pancreatitis;IgG4-related Sclerosing Cholangitis;Retroperitoneal Fibrosis | Drug: Rituximab;Drug: Lenalidomide | Mayo Clinic | Celgene Corporation | Not recruiting | 18 Years | N/A | All | 6 | Phase 1 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT02703194 | March 2016 | 18 March 2019 | Leflunomide for Maintenance of Remission in IgG4 Related Disease | A Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related Disease | Immunoglobulin G4 Related Sclerosing Disease | Drug: Prednisone;Drug: Leflunomide | Chinese PLA General Hospital | Not recruiting | 18 Years | 80 Years | All | 68 | Phase 4 | China | |
| 12 | NCT02725476 | March 2016 | 18 December 2018 | Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD) | An Open-label, Single-arm, Pilot Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease | IgG4-RD | Biological: XmAb5871 | Xencor, Inc. | Massachusetts General Hospital | Not recruiting | 18 Years | 80 Years | All | 20 | Phase 2 | United States |
| 13 | JPRN-UMIN000019908 | 2016/01/01 | 2 April 2019 | Preliminary study of [11C]methionine PET/CT in the diagnosis of IgG4 related disease | IgG4 related disease | [11C]methionine PET/CT, [18F]FDG PET/CT | Saitama Medical University International Medical Center | Saitama Medical University Hospital | Not Recruiting | 20years-old | Not applicable | Male and Female | 30 | Not selected | Japan | |
| 14 | NCT02458196 | April 2015 | 16 December 2017 | Study of Treatment Response on IgG4 Related Disease (IgG4RD) | A Randomized Trial of Treatment in Patients With IgG4-Related Disease | Autoimmune Disease | Drug: Prednisone;Drug: Prednisone and Mycophenolate mofetil | Peking Union Medical College Hospital | Recruiting | 18 Years | 70 Years | All | 60 | Phase 2 | China | |
| 15 | NCT01758393 | December 2012 | 19 February 2015 | Glucocorticoids in Patients With IgG4-RD | A Randomized Trial of Glucocorticoids in Patients With IgG4-Related Disease | IgG4-related Disease | Drug: Prednisone | Peking Union Medical College Hospital | Recruiting | 18 Years | 70 Years | Both | 40 | Phase 2/Phase 3 | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT01665196 | September 2012 | 16 December 2017 | 18F-FDG PET/CT for IgG4-Related Disease | Evaluation of 18F-FDG PET/CT in Diagnosis and Response Assessment of Patients With IgG4-Related Disease | Autoimmune Disease | Drug: 18F-FDG | Peking Union Medical College Hospital | Recruiting | 18 Years | 75 Years | All | 100 | Early Phase 1 | China | |
| 17 | NCT02899039 | July 2012 | 26 September 2016 | Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease | Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease | IgG4-related Disease | Biological: extra blood draw samples | Assistance Publique Hopitaux De Marseille | Not recruiting | 18 Years | N/A | Both | 75 | N/A | France | |
| 18 | NCT01584388 | April 2012 | 16 December 2017 | Rituximab in IgG4-RD: A Phase 1-2 Trial | Rituximab (RTX) for IgG4-related Disease (IgG4-RD): a Prospective,Open-label Trial | Retroperitoneal Fibrosis;Autoimmune Pancreatitis;Sialadenitis;Pseudotumor | Drug: Rituximab | Massachusetts General Hospital | Genentech, Inc. | Not recruiting | 18 Years | N/A | All | 30 | Phase 1/Phase 2 | United States |
| 19 | JPRN-UMIN000003804 | 2010/05/01 | 2 April 2019 | Randomized controlled trial which examines whether resuming steroid can prevent clinical relapse in the patients with asymptomatic high levels of serum IgG after ceasing steroid therapy for autoimmune pancreatitis | autoimmune pancreatitis | Prednisolone at a dose of 10mg/day is started. The dose is taperd by 2.5mg every 8-10 weeks until reaching 5mg/day. Maintenance therapy at a dose of 5 mg/day is continued. Resuming or increasing prednisolone is not planned. Patients during the course of tapering prednisolone continue to taper the dose until its complete cessation. | Department of Gastroenterology, University of Tokyo | Recruiting | 20years-old | Not applicable | Male and Female | 20 | Not applicable | Japan | ||
| 20 | NCT00588367 | April 2006 | 28 April 2015 | CT Pancreas Perfusion | CT Perfusion of Pancreatic Cancer and Chronic Pancreatitis: Feasibility Study | Pancreatic Ductal Adenocarcinoma;Chronic Pancreatitis;Autoimmune Pancreatitis | Device: Mayo Interactive Breath Hold Monitor | Mayo Clinic | Not recruiting | 18 Years | N/A | Both | 30 | N/A | United States |